This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Dentsply International (XRAY) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 28.95% and 3.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
by Zacks Equity Research
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
XRAY or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
by Zacks Equity Research
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
Here's Why You Should Bet on Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across its segments and prudent acquisitions.
BD Introduces New Product to Reduce the Risk of Sepsis
by Zacks Equity Research
BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.
Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
Strong prospects in emerging markets provide DENTSPLY (XRAY) a competitive edge in the MedTech space.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Dentsply (XRAY) Up 18.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Momentum Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st
XRAY vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Will DENTSPLY SIRONA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DENTSPLY SIRONA.
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.